Fierce Biotech April 26, 2024
Max Bayer, Gabrielle Masson, Andrea Park

Welcome to this week’s Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Max Bayer or Gabrielle Masson, and we will feature it here at the end of each week.

Ousted former Stanford president tapped to lead new billion-dollar biotech

Xaira Therapeutics

Last year was a difficult one for ex-Stanford president Marc Tessier-Lavigne, Ph.D. An investigation into his prior research from the campus’s student newspaper ultimately led to his resignation. But the once-chief scientific officer of Genentech is now back in biotech.

Tessier-Lavigne has been tapped to lead Xaira Therapeutics, which emerged this week with a whopping $1 billion (yes, with a “B”) in new capital...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
FTC wants more information on Novo's $16.5B deal to boost Wegovy production
FDA flags 10 observations in another Form 483 for a Zydus plant
Gates, Novo Nordisk And Wellcome Commit $300 Million To Climate Change, Infectious Diseases And Nutrition
Senate tackles drug shortages with new legislation
Opinion: The world is relying on the United States to get value-based drug pricing right

Share This Article